Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis
| Autor: | David I. Wolf, Mark Lebwohl, Tania J. Phillips, Janine M. Quell, Stanley I. Cullen, Roshantha A.S. Chandraratna, Nicholas J. Lowe, Theodore Rosen, John C. Lue, John R. Gibson, Ernest Ast, John Sefton, Carol L. Kulp-Shorten, Jeffrey P. Callen, Steven Hong |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Erythema Adolescent medicine.medical_treatment Anti-Inflammatory Agents Fluocinonide Dermatology Administration Cutaneous law.invention Randomized controlled trial Tazarotene law Psoriasis Medicine Humans Life Tables Prodrugs Single-Blind Method Child Glucocorticoids Aged Skin Aged 80 and over Chemotherapy Analysis of Variance business.industry Therapeutic effect Nicotinic Acids Middle Aged medicine.disease Clinical trial Treatment Outcome Female Dermatologic Agents medicine.symptom Safety business Gels medicine.drug Follow-Up Studies |
| Zdroj: | Journal of the American Academy of Dermatology. 38(5 Pt 1) |
| ISSN: | 0190-9622 |
| Popis: | Background: A new class of topical receptor-selective acetylenic retinoids, the first of which is tazarotene, has been developed. Objective: Our purpose was to compare the safety, efficacy, and duration of therapeutic effect of 12 weeks of once-daily tazarotene 0.1% and 0.05% gel with that of twice-daily fluocinonide 0.05% cream in the treatment of patients with plaque psoriasis. Methods: Three hundred forty-eight patients with plaque psoriasis were enrolled and 275 patients completed a multicenter, investigator-masked, randomized, parallel-group clinical trial. Results: Both tazarotene gels were as effective as fluocinonide in reducing plaque elevation after 1 week of treatment, and tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of trunk/limb lesions at all study weeks except week 4. Tazarotene 0.1% gel was similar to fluocinonide in reducing scaling of knee/elbow lesions at weeks 8 and 12. Fluocinonide had a significantly greater effect on erythema than tazarotene at weeks 2 through 8. However, treatments were not significantly different at week 12, and tazarotene demonstrated significantly better maintenance of therapeutic effect after cessation of therapy. Conclusion: Tazarotene 0.1% and 0.05% gels were safe and effective in the treatment of mild-to-moderate plaque psoriasis.(J Am Acad Dermatol 1998;38:705-11.) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect